Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients
Abstract Background Observational studies suggest that loss of skeletal muscle mass (SMM) is associated with chemotherapy‐related toxicity, poor quality of life, and poor survival in metastatic colorectal cancer (mCRC) patients. Little is known about the evolution of SMM during palliative systemic t...
Main Authors: | Sophie A. Kurk, Petra H.M. Peeters, Bram Dorresteijn, Pim A. deJong, Marion Jourdan, Hugo J. Kuijf, Cornelis J.A. Punt, Miriam Koopman, Anne M. May |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-10-01
|
Series: | Journal of Cachexia, Sarcopenia and Muscle |
Subjects: | |
Online Access: | https://doi.org/10.1002/jcsm.12337 |
Similar Items
-
Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients
by: Sophie Kurk, et al.
Published: (2019-08-01) -
Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial
by: Sophie A. Kurk, et al.
Published: (2020-02-01) -
The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer
by: Jeroen W.G. Derksen, et al.
Published: (2020-08-01) -
Association between Elevated Plasma Homocysteine and Low Skeletal Muscle Mass in Asymptomatic Adults
by: Jae-Hyeong Choi, et al.
Published: (2022-04-01) -
Manifestations of Age on Autophagy, Mitophagy and Lysosomes in Skeletal Muscle
by: Matthew Triolo, et al.
Published: (2021-04-01)